MoneyWorks4Me

Mahamaya Lifesciences Ltd (544611)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544611 NSE: Pesticides & Agrochemicals | Small Cap | Mahamaya Lifescience Share Price

₹172.55 -8.15 (-4.51%)

As on 21-Oct'26 16:59

Mahamaya Lifesciences Ltd (544611)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544611 NSE: Pesticides & Agrochemicals | Small Cap | Mahamaya Lifescience Share Price

₹172.55 -8.15 (-4.51%)

As on 21-Oct'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹404 Cr.
Current Price
₹172.6
52-Week Low / High
₹111 / 205
TTM EPS
₹7.1
TTM Sales
₹329 Cr.
Book Value per Share
₹52.1
P/E Ratio
24.44
Lower than its 5-year historical median
Industry PE
25.6
Price to Book (P/B)
3.31
Lower than its 5-year historical median
Price to Sales (P/S)
1.23
Lower than its 5-year historical median
EV/EBITDA
13.12
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
19.29%
Outperforms industry median
Return on Capital Employed (ROCE)
20.27%
Outperforms industry median
Return on Assets (ROA)
6.63%
Operating Profit Margin
11.5%
Net Profit Margin
5.02%
Gross Profit Margin
7.9%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
23.91%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
37.34%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
28.96%
Asset Quality
Promoter Holding
56.35%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹99 Cr.
Equity
₹23.4 Cr.
Face Value
₹10
All Time Low / High
₹111.00 / 205.05

Mahamaya Lifesciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Fair

Price Trend

Weak
Q.1 Is Mahamaya Lifesciences Ltd a good quality company?
Mahamaya Lifesciences Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Mahamaya Lifesciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Mahamaya Lifesciences Ltd vs industry peers?
Mahamaya Lifesciences Ltd revenue CAGR is 43.51%, compared to the industry median CAGR of 0.14%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Mahamaya Lifesciences Ltd?
Promoters hold 56.35% of the Mahamaya Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Mahamaya Lifesciences Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Mahamaya Lifesciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ16.5%20.6%21.8%26%20.3%-
Value Creation
Index ⓘ
0.20.50.60.9NA-

Growth Parameters ⓘ

Sales ⓘ89.9137162266329329
Sales YoY Gr.-52.5%17.9%64.5%23.9%-
Adj EPS ⓘ233.76.98.37.1
YoY Gr.-47.1%24.7%83.2%21.3%-
BVPS (₹) ⓘ11.614.418.328.152.452.4
Adj Net
Profit ⓘ
2.84.15.112.219.517
Cash Flow from Ops. ⓘ1.90.8-23.5-0.5-29.6-
Debt/CF from Ops. ⓘ10.130-2.3-123.5-3.1-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANA33.9%23.9%
Adj EPS ⓘNANA40.4%21.3%
BVPSⓘNANA54%86.6%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ
17.523.122.932.422.613.6
Op. Profit
Mgn % ⓘ
7.37.18.59.311.6NAN
Net Profit
Mgn % ⓘ
3.133.24.65.95.1
Debt to
Equity ⓘ
1.21.22.21.20.7-
Working Cap
Days ⓘ
01151561642120
Cash Conv.
Cycle ⓘ
03080991330

Valuation of Mahamaya Lifescience - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26
Sales90137162266329
Operating Expenses ⓘ + 84128148241295
Manufacturing Costs12377
Material Costs73116136219266
Employee Cost 33356
Other Costs ⓘ 6761016
Operating Profit ⓘ 69132534
Operating Profit Margin (%) 7.1%6.7%8.3%9.3%10.3%
Other Income ⓘ + 00111
Exceptional Items ⓘ 00000
Interest ⓘ 23679
Depreciation ⓘ 11122
Profit Before Tax ⓘ 4571724
Tax ⓘ 11247
Profit After Tax 3451317
PAT Margin (%) 3.0%2.7%3.2%4.8%5.0%
Adjusted EPS (₹)2.02.73.87.27.1
Dividend Payout Ratio (%)0%0%0%0%0%
PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 16192549122
Share Capital ⓘ 1.251.251.2517.7723.41
Reserves ⓘ 1418233299
Debt +1822525588
Long Term Debt1010964
Short Term Debt812434984
Minority Interest00000
Trade Payables1728235564
Others Liabilities ⓘ 69132936
Total Liabilities ⓘ 5678112188310

Fixed Assets

Net Fixed Assets ⓘ +1820202735
Gross Block2023253343
Accumulated Depreciation33468
CWIP ⓘ 22348
Investments ⓘ 00000
Inventories193551100141
Trade Receivables910284871
Cash Equivalents 133439
Others Assets ⓘ 686516
Total Assets ⓘ 5678112188310
PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 21-23-0-30
PBT ⓘ 4571724
Adjustment ⓘ 357810
Changes in Working Capital ⓘ -3-8-35-24-59
Tax Paid ⓘ -1-1-1-2-4
Cash Flow From Investing Activity ⓘ + -3-3-2-7-16
Capex -3-3-2-7-16
Net Investments 00000
Others ⓘ 00000
Cash Flow From Financing Activity ⓘ + 1224981
Net Proceeds from Shares ⓘ 0001256
Net Proceeds from Borrowing ⓘ 000-2-3
Interest Paid ⓘ -2-3-6-7-8
Dividend Paid ⓘ 00000
Others ⓘ 3530535
Net Cash Flow ⓘ 01-0135
PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)17.3421.3423.6734.5919.29
ROCE (%)16.1220.8121.5226.0920.27
Asset Turnover Ratio1.622.051.71.771.32
PAT to CFO Conversion(x)0.670.25-4.6-0-1.76
Working Capital Days
Receivable Days3724.8042.7052.7066.10
Inventory Days75.6071.1096.90103.90133.70
Payable Days82.7069.4067.5064.9082

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Mahamaya Lifesciences Ltd FAQs

The current trading price of Mahamaya Lifescience on 21-Oct-2026 16:59 is ₹172.6.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Oct-2026 the market cap of Mahamaya Lifescience stood at ₹403.9 Cr

The latest P/E ratio of Mahamaya Lifescience as of 20-Oct-2026 is 24.15.

The latest P/B ratio of Mahamaya Lifescience as of 20-Oct-2026 is 3.29.

The 52-week high of Mahamaya Lifescience is ₹205.1 and the 52-week low is ₹111.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Mahamaya Lifescience is ₹329 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Mahamaya Lifesciences Ltd is a below average quality company.

The key valuation ratios of Mahamaya Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Mahamaya Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Mahamaya Lifesciences Ltd

Mahamaya Lifesciences was originally incorporated as a private limited Company under the name of ‘Mahamaya Life Sciences Private Limited’ on May 07, 2002. Further, the company name was changed from ‘Mahamaya Life Sciences Private Limited’ to ‘Mahamaya Lifesciences Private Limited’ and a fresh certificate of Incorporation dated February 15, 2016 was issued by the Registrar of Companies, Delhi. Moreover, a special resolution was passed at the Extra-Ordinary General Meeting of the company held on October 29, 2024 for conversion of the company into a public limited company and the name of the company was changed from ‘Mahamaya Lifesciences Private Limited’ to ‘Mahamaya Lifesciences Limited’ on November 19, 2024.

The company specializes in the manufacturing of pesticide formulations and supply bulk formulations catering to both Indian agrochemical companies, as well as multinational corporations (MNCs). It began its journey by focusing on import and registration of vital pesticide molecules (Technical) that were not produced domestically in India. It imported these molecules after lot of product research and worked on registering them with the Central Insecticides Board and Registration Committee (CIBRC) under the Department of Agriculture, Government of India. After successful registration it marketed these molecules both as technical and as value added end use formulations for both domestic manufacturers and MNCs. 

The company, backed by over three decades of experience from its promoters, and senior managerial personnel possesses a deep understanding of both Technical and formulation supplies, which are essential to the pesticide industry. It specialises in safer environment friendly products. With its research and development capabilities, it identifies the latest, safer molecules, conducts field trials at State Agricultural Universities and carries out toxicology and chemistry studies at CIBRC approved laboratories. It invests in registration of new molecules, which are, once approved and registered are distributed within India. With an advanced formulation plant, the company supplies products across the country and has marketing agreements with multinationals corporations.

Leveraging the extensive experience of its promoter and managing director Krishnamurthy Ganesan, in the agrochemical industry, it has played a key role in shaping its expertise in identifying high-growth products, securing their registration with the CIBRC, and conducting comprehensive Research & Development. Its emphasis is on cultivating strong relationship with both domestic companies and multinational corporations. It is focused on developing and expanding biological crop care products including bio stimulant formulations, plant growth regulators, bio fertilizers, as well as new age bio-fermented insecticides, fungicides and herbicides all designed to be low in toxicity and eco-friendly.

The sales of its branded products across various states are managed by its experienced sales team, who have extensive product knowledge and market expertise. Each state is supported by a dealer network, ensuring the brand's business is handled effectively and efficiently, with a strong focus on meeting customer needs and maintaining consistent product availability. Its branded products are dispatched from its factory to warehouses/godowns in various states, and subsequently distributed to dealers, who sell them to farmers.

Business area of the company

The company specializes in the manufacturing of pesticide formulations and supply bulk formulations catering to both Indian agrochemical companies, as well as multinational corporations (MNCs). It began its journey by focusing on import and registration of vital pesticide molecules (Technical) that were not produced domestically in India. It imported these molecules after lot of product research and worked on registering them with the Central Insecticides Board and Registration Committee (CIBRC) under the Department of Agriculture, Government of India. After successful registration it marketed these molecules both as technical and as value added end use formulations for both domestic manufacturers and MNCs.

Products categories of the company

  • Bulk Formulations Sales 
  • Technical Sales 
  • Brand Sales (own brand product) 
  • Exports- Formulations

Awards and recognitions

  • 2023: One of the top 10 Pesticides and Insecticides Manufacturers

History and millstones

  • 2002: Incorporation of the Company in the name and style of ‘Mahamaya Life Sciences Private Limited’ under Companies Act, 1956.
  • 2016: Company name was changed from ‘Mahamaya Life Sciences Private Limited’ to ‘Mahamaya Lifesciences Private Limited’.
  • 2018: The Company received CTE from the Gujarat Pollution Control Board, and then began construction of factory in Dahej, Gujarat.
  • 2021: The factory plant was completed and after obtaining License to Manufacture Insecticides from Directorate of Agriculture, Government of Gujarat, formulations of insecticide were started in the factory.
  • 2024: Conversion of the Company from private limited to public limited.

You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now